Author: Suddala, Krishna C.; Lee, Christine C.; Meraner, Paul; Marin, Mariana; Markosyan, Ruben M.; Desai, Tanay M.; Cohen, Fredric S.; Brass, Abraham L.; Melikyan, Gregory B.
Title: Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes Document date: 2019_1_14
ID: 15wxk8lt_5
Snippet: The most popular view of the mechanism of IFITM's antiviral activity is that these proteins create "tough membranes" that are not conducive to fusion [17, 18, 22] . Two principal models for membrane stiffening by IFITMs have been proposed-a direct effect on the membrane in the immediate proximity of these proteins [19, 25, [33] [34] [35] that could involve changing the membrane fluidity and/or curvature [22, 33, 35] , and an indirect effect throu.....
Document: The most popular view of the mechanism of IFITM's antiviral activity is that these proteins create "tough membranes" that are not conducive to fusion [17, 18, 22] . Two principal models for membrane stiffening by IFITMs have been proposed-a direct effect on the membrane in the immediate proximity of these proteins [19, 25, [33] [34] [35] that could involve changing the membrane fluidity and/or curvature [22, 33, 35] , and an indirect effect through altering the lipid composition of endosomes [18] . Several lines of evidence support the proximity-based antiviral activity of IFITMs. First, as discussed above, there is a general correlation between the subcellular localization of IFITMs and their potency against viruses entering from distinct cellular compartments (reviewed in [17] ). Second, IFITM3-mediated restriction, but not restriction by the plasma membrane-resident IFITM1, can be bypassed by forcing virus fusion with the plasma membrane [25, 30] . Third, IFITM incorporation into the viral membrane effectively inhibits fusion/infectivity [34, [36] [37] [38] . On the other hand, IFITM3 has been reported to bind to and inhibit the function of vesicle-associated membrane protein-associated protein A (VAPA) [18] , the master regulator of endosome-ER lipid transport. While this model has been disputed by several groups [30, 35] , a recent study provided evidence for the antiviral effect of cholesterol accumulation in late endosomes/lysosomes and confirmed accumulation of cholesterol in these compartments upon IFITM3 expression [39] . It thus remains unclear whether IFITMs must be present at the sites of virus fusion to block virus entry or affect fusion indirectly, by dysregulating lipid transport or metabolism.
Search related documents:
Co phrase search for related documents- protein associate and virus entry: 1, 2
- protein associate and virus fusion: 1, 2, 3
- recent study and subcellular localization: 1
- recent study and viral membrane: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- recent study and virus entry: 1, 2, 3, 4, 5, 6, 7
- recent study and virus fusion: 1, 2, 3
- subcellular localization and viral membrane: 1, 2, 3, 4, 5, 6, 7
- subcellular localization and virus entry: 1, 2, 3, 4, 5
- subcellular localization and virus fusion: 1
- viral membrane and virus entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- viral membrane and virus entry block: 1, 2, 3, 4, 5
- viral membrane and virus fusion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- viral membrane and virus fusion site: 1
Co phrase search for related documents, hyperlinks ordered by date